Fair Value Calculator Fair Value Calculator
EN DE

Mytrex Health Technologies, Inc (4431) Fair Value & Analysis

Industrials · TW · Market cap 608M TWD

MH Mytrex Health Technologies, Inc 4431 · TWO
Price17.10 TWD
Fair Value21.18 TWD
Upside+23.9%
Quality55/100
Watch Mytrex Health Technologies, Inc for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range 16.21 TWD – 26.14 TWD

Fair value as of: Jul 11, 2026

From 13 valuation models · updated today

Fair value updated Jul 11, 2026 — revised from 70.60 TWD to 21.18 TWD (−70.0%) since Jun 24, 2026. Share price +3.6% over the past month.

Price vs Fair Value (12 months)

21.40 TWD 16.05 TWD Fair Value 21.18 TWD Jun 2025 Jul 2026

12‑month range 16.05 TWD – 21.40 TWD · fair‑value band 16.21 TWD – 26.14 TWD · the 17.10 TWD price screens below the 21.18 TWD fair value. As of Jul 11, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Mytrex Health Technologies, Inc (4431) currently trades at 17.10 TWD, while our model-based Fair Value estimate is 21.18 TWD — implying the stock looks roughly 23.9% undervalued today. We read business quality at 55/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, Mytrex Health Technologies, Inc generated revenue of 1.9B TWD at a net margin of -0.9%. Revenue grew 3.5% year over year. It earns a return on equity of -4.3%. The balance sheet holds a net cash position of 48.6M TWD. Fundamentals as of Jul 11, 2026

Our scenario range runs from 16.21 TWD (bear case) to 26.14 TWD (bull case); at 17.10 TWD, the current price sits within that range. The share trades about 26% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -50% fair-value upside — at 24%, 4431 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 1.9B TWD
Revenue growth (YoY) +3.5%
Net margin -0.9%
Return on equity -4.3%
Free cash flow 195M TWD FY2025
Operating margin -0.4%
More key figures
EPS (TTM) -0.4500 TWD
Net cash 48.6M TWD FY2024

Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.

About the company

Mytrex Health Technologies, Inc. engages in the manufacturing, processing, and sale of various filter non-woven fabrics in Taiwan, rest of Asia, Europe, and internationally. The company provides electrostatic filtration materials for medical and industrial mask media, and other filtration applications; and composite nonwoven products for coolant and air filter, vacuum filter bag, HEPA and cabin filter, and water filtration compound material applications. It also offers thermal insulation products for glove, sock, shoe, hat, clothing material, and mask insulation material applications; and linen laundry and leasing, logistic, and medical supplies for hospitals. In addition, the company sells pharmaceuticals and medical hygiene materials; and manages medical clothing products. Mytrex Health Technologies, Inc. was founded in 1990 and is based in Taoyuan City, Taiwan.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Mytrex Health Technologies, Inc reported revenue of 1.9B TWD in FY2025 versus 292M TWD in FY2021, a compound +60.7%/yr. Reported net income was −16.6M TWD in FY2025.

Revenue +60.7%/yr
FY21 292M TWD
FY22 1.5B TWD
FY23 1.3B TWD
FY24 1.8B TWD
FY25 1.9B TWD
Net income
FY21 −14.0M TWD
FY22 −91.9M TWD
FY23 −56.2M TWD
FY24 −82.4M TWD
FY25 −16.6M TWD

Is 4431 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Mytrex Health Technologies, Inc Fair Value". https://www.fairvalue-calculator.com/stock/4431

Similar stocks

10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Stock Price Fair Value vs Fair Value
GE Vernova Inc 1GEV €967.60 €212.97 -78%
1SIE 1SIE €284.30 €122.46 -57%
SIEGY SIEGY $155.10 $88.93 -43%
SMAWF SMAWF $307.12 $176.28 -43%
SMNS SMNS C$31.76 C$22.85 -28%
SIE SIE €279.00 €140.38 -50%
Schneider Electric S.E. SBGSF $326.83 $147.43 -55%
Siemens Energy AG SMEGF $192.99 $47.30 -75%
Eaton Corporation ETN $418.61 $207.98 -50%
Atlas Copco AB ATCOA kr 179.35 kr 122.65 -32%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Mytrex Health Technologies, Inc (4431) undervalued?
As of Jul 11, 2026, our model estimates a fair value of 21.18 TWD versus a price of 17.10 TWD — about +24% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 4431?
Our model-based fair value for Mytrex Health Technologies, Inc is 21.18 TWD (as of Jul 11, 2026), built from audited fundamentals. The current price is 17.10 TWD.
What is the quality score of 4431?
Mytrex Health Technologies, Inc has a Quality Score of 55/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Mytrex Health Technologies, Inc (4431)?
Mytrex Health Technologies, Inc reported trailing-twelve-month revenue of about 1.9B TWD (latest available figure, as of Jul 11, 2026).
What is the net profit margin of 4431?
The net profit margin of Mytrex Health Technologies, Inc is about -0.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

The 25 strongest value stocks, free every month

Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.